Psoriasis drug OTEZLA tested in everyday use
NCT ID NCT03284879
First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 2 times
Summary
This completed study observed over 1,000 people with psoriasis who were prescribed OTEZLA (apremilast) for the first time. Researchers tracked side effects, symptom improvement, and quality of life over several years. The goal was to see how well the drug works in real-world settings, outside of a controlled clinical trial.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Apremilast (OTEZLA)
- What this could lead to
- If successful, this study could confirm that OTEZLA is a safe and effective option for managing psoriasis in everyday medical practice.
- What could go wrong
- This is an observational study, not a controlled trial, so results may be less reliable. It also does not compare OTEZLA to other treatments or a placebo.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PSORIASIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Tugi dermatology clinic
Kitakyushu, Fukuoka, 804-0081, Japan
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new gel calm psoriasis Flare-Ups?
- Can a Once-Daily cream tame psoriasis in toddlers?
- Can a switch to guselkumab clear stubborn psoriasis?
- Can a new biologic clear stubborn psoriasis?
- Diet and exercise may tame psoriasis in kids — a trial puts it to the test
- Ancient herbal mix put to the test against psoriasis